NCT05503901View on ClinicalTrials.gov

A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
DRUG

STN1012600 ophthalmic solution 0.002%

1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks

DRUG

STN1012600 ophthalmic solution 0.002%

1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks

DRUG

STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%

1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks

Trial Locations (18)

Unknown

Kitanagoya Eye Clinic, Aichi

Miyake Eye Hospital, Aichi

Nagasaka Eye Clinic, Aichi

Eto Eye Clinic, Fukuoka

Minamoto Eye Clinic, Hiroshima

Matsumoto Eye Clinic, Ibaraki

IGO Ophthalmic Clinic, Kagoshima

Ohguchi Ophthalmic Clinic, Kanagawa

Smile Eye Clinic, Kanagawa

Inamoto Eye Clinic, Osaka

Kubota Eye Clinic, Osaka

Nishi Eye Hospital, Osaka

Onoe Eye Clinic, Osaka

Red Cross Ogawa Hospital, Saitama

Nakajima Eye Clinic, Shizuoka

Hashida Eye Clinic, Tokyo

Seijo Clinic, Tokyo

Sinzyuku Eye Clinic, Tokyo

All Listed Sponsors
lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY